Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
作者信息
Piehl Fredrik, Hillert Jan
机构信息
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden/Department of Neurology, Karolinska University Hospital, Stockholm, Sweden/Neuroimmunology Unit, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden/Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
出版信息
Mult Scler. 2018 Aug;24(9):1157-1159. doi: 10.1177/1352458518757930. Epub 2018 Feb 22.
PMID:29468952
Abstract
摘要
Zotero 插件